Harmony Biosciences (HRMY) Stock Price, News & Analysis

Company Overview

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders, particularly excessive daytime sleepiness and cataplexy associated with narcolepsy. The company’s activities encompass research, clinical development, regulatory submissions and commercialization efforts in the field of sleep medicine. Harmony is committed to advancing treatment options for underserved patient populations and improving long-term outcomes through targeted therapies.

The company’s flagship product, Wakix (pitolisant), is a first-in-class histamine H3 receptor antagonist/inverse agonist approved in the United States and Europe for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. Harmony is also developing HBS-102, an investigational therapy designed to address idiopathic hypersomnia, which is currently advancing through clinical trials. In addition to its own pipeline, Harmony collaborates with strategic partners to expand the reach of its therapies globally and to explore new indications.

Founded in 2018 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences emerged with a mission to fill gaps in care for patients suffering from central nervous system disorders. The company went public in March 2019, raising capital to accelerate its research and development programs. Under the leadership of President and Chief Executive Officer George Dunham, Harmony has built a specialized team of experts in neuroscience, clinical operations and regulatory affairs.

Harmony’s operations extend beyond the United States through regulatory approvals in Europe and commercial partnerships designed to bring its therapies to additional markets. The company continues to invest in clinical research, patient support programs and physician education in order to enhance awareness of rare sleep disorders and to ensure access to its treatments. Harmony’s strategic focus remains on leveraging scientific innovation to address unmet needs and improve quality of life for patients worldwide.

Key Stats

• Today's Range: $33.07 to $34.36
• 50-Day Range: $29.47 to $35.91
• 52-Week Range: $26.47 to $41.61
• Volume: 511,831 shs
• Average Volume: 633,463 shs
• Market Capitalization: $1.97 billion
• P/E Ratio: 13.09
• Dividend Yield: N/A
• Price Target: $53.63
• Consensus Rating: Buy

Harmony Biosciences Stock Analysis - MarketRank™

Harmony Biosciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 50th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Harmony Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 27.98%

Earnings Growth

Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Harmony Biosciences is 12.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harmony Biosciences is 12.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.55.

Price to Earnings Growth Ratio

Harmony Biosciences has a PEG Ratio of 0.48. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Harmony Biosciences has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.51% of the float of Harmony Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Harmony Biosciences has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Harmony Biosciences has recently increased by 9.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harmony Biosciences does not currently pay a dividend.

Dividend Growth

Harmony Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.51% of the float of Harmony Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Harmony Biosciences has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Harmony Biosciences has recently increased by 9.76%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Harmony Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

Search Interest

13 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.

MarketBeat Follows

3 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HRMY Stock Analysis - Frequently Asked Questions

How have HRMY shares performed this year?

Harmony Biosciences' stock was trading at $34.41 at the start of the year. Since then, HRMY shares have decreased by 1.7% and is now trading at $33.8340.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released its earnings results on Tuesday, May, 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. The business's revenue for the quarter was up 19.5% compared to the same quarter last year.
Read the conference call transcript.

When did Harmony Biosciences IPO?

Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Who are Harmony Biosciences' major shareholders?

Top institutional investors of Harmony Biosciences include Livforsakringsbolaget Skandia Omsesidigt (0.04%) and Gallacher Capital Management LLC (0.02%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks.
View institutional ownership trends.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HRMY
• CIK: 1802665
• Web: www.harmonybiosciences.com
• Phone: 484-539-9800
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Harmony Biosciences: $53.63
• High Price Target: $70.00
• Low Price Target: $40.00
• Potential Upside/Downside: +56.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.62
• Trailing P/E Ratio: 13.09
• Forward P/E Ratio: 14.11
• P/E Growth: 0.48
• Net Income: $145.49 million
• Net Margins: 20.53%
• Pretax Margin: 26.48%
• Return on Equity: 24.32%
• Return on Assets: 15.92%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 3.67
• Quick Ratio: 3.63

Sales & Book Value

• Annual Sales: $714.73 million
• Price / Sales: 2.75
• Cash Flow: $3.13 per share
• Price / Cash Flow: 10.94
• Book Value: $11.56 per share
• Price / Book: 2.97

Miscellaneous

• Outstanding Shares: 57,420,000
• Free Float: 43,872,000
• Market Cap: $1.97 billion
• Optionable: Optionable
• Beta: 0.83